Even NK-92 cells transfected with CD19-CAR or CD20-CAR, or redirected against different tumor antigens by adapter CAR technology using biotinylated antibodies as adapter molecules, have been shown to induce significant lysis of primary CLL cells and to contrast tumor antigen evasion mechanisms [294,295,296]. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.